ClinicalTrials.gg
RecruitingNCT07524829Updated Apr 13, 2026

Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients

An interventional study of Structured Telenursing Follow-up and Standard Nursing Care in Breast Cancer, Drug-Related Side Effects and Adverse Reactions and Chemotherapy Toxicity, sponsored by Azienda Sanitaria Locale di Asti. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Azienda Sanitaria Locale di Asti · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2024, registered Apr 2026).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Planned enrollment
435th of 687
124 · median 208
Started
2024
with 63 others
No phase
161 of 887
53 open now
Primary completion
2028-04
later than 258 of 349 live
Registered
865th of 887
by date

Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 435th largest by planned enrollment of the 687 interventional ones that give a count, is one of 64 that started in 2024, is one of 161 with no phase, reaches primary completion later than 258 of the 349 other live ones, and was the 865th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

226 more — sign in →

All 231 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 887 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.

Patients undergoing treatment with CDK inhibitors frequently experience adverse effects that may negatively impact treatment adherence, quality of life, and clinical outcomes. Early detection and timely management of these side effects are essential to optimize therapy and reduce complications, including unplanned hospitalizations and treatment interruptions.

In this study, participants are randomly assigned to one of two groups: standard care or standard care plus a structured telenursing follow-up program. The intervention consists of scheduled remote contacts (telephone or video consultations) conducted by trained nursing staff at predefined time points during treatment. These contacts aim to monitor symptoms, provide education, reinforce adherence, and facilitate early identification and management of treatment-related toxicities.

The primary objective of the study is to assess whether the telenursing intervention reduces the incidence and severity of treatment-related adverse events compared to standard care alone. Secondary objectives include evaluating its impact on emergency department visits, hospitalizations, treatment adherence, dose intensity, and patient-reported outcomes.

The study is currently recruiting participants across multiple centers. Results from this trial may provide evidence to support the integration of structured telenursing programs into routine oncology care, with the potential to improve patient safety, treatment continuity, and overall clinical outcomes.

Read the detailed description

Breast cancer patients receiving cyclin-dependent kinase (CDK) inhibitors represent a growing population in oncology practice. These therapies, although highly effective, are frequently associated with a range of treatment-related adverse events, including hematologic toxicities (such as neutropenia), gastrointestinal symptoms, fatigue, and other systemic effects. These side effects may lead to treatment interruptions, dose reductions, decreased adherence, and increased healthcare utilization, including unplanned emergency department visits and hospitalizations.

Early detection and proactive management of treatment-related toxicities are essential to ensure treatment continuity and optimize clinical outcomes. In routine clinical practice, however, symptom monitoring is often limited to scheduled outpatient visits, which may delay the identification and management of adverse events. Innovative care models, including telemedicine and telenursing interventions, have been proposed to enhance patient monitoring and support between visits.

The present study (NURSING PRE-EFFECT) is a multicenter, randomized, controlled, open-label clinical trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer undergoing treatment with CDK inhibitors. The study aims to assess whether the integration of scheduled remote nursing follow-up can improve early detection and management of treatment-related adverse events and positively influence clinical outcomes.

This study is a randomized, parallel-group interventional trial. Participants are prospectively assigned to one of two arms using a computerized randomization system: (1) a telenursing intervention group receiving standard care plus a structured telenursing program, and (2) a control group receiving standard care alone.

Standard care consists of routine clinical and nursing management according to local practice at each participating center. The study aims to compare the effectiveness of the telenursing intervention in improving early detection and management of treatment-related adverse events.

The experimental intervention consists of a structured telenursing follow-up program delivered by trained oncology nurses. The program includes scheduled remote contacts (telephone calls or video consultations) at predefined time points during treatment (e.g., at approximately day 7, day 14, and day 21 of each treatment cycle, or according to protocol specifications). During these contacts, nurses systematically assess patient-reported symptoms, monitor treatment-related toxicities, provide education on symptom management, reinforce treatment adherence, and identify early warning signs requiring clinical intervention.

When clinically relevant symptoms or adverse events are identified, patients are promptly referred to the treating physician or appropriate healthcare services for further evaluation and management, according to predefined clinical pathways. This proactive approach aims to reduce delays in care, prevent worsening of toxicities, and minimize the need for acute care services.

The primary objective of the study is to evaluate the effect of the telenursing intervention on the incidence and severity of treatment-related adverse events, assessed using standardized criteria (e.g., Common Terminology Criteria for Adverse Events, CTCAE).

Secondary objectives include:

evaluation of the impact on unplanned emergency department visits and hospitalizations; assessment of treatment adherence and relative dose intensity; evaluation of treatment modifications (dose reductions, delays, or discontinuations); assessment of patient-reported outcomes, including quality of life and satisfaction with care; evaluation of healthcare resource utilization.

Data are collected prospectively using standardized case report forms and institutional electronic health records. Clinical, treatment-related, and outcome data are recorded at baseline, during treatment, and at predefined follow-up time points.

The study is conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval has been obtained from the competent Ethics Committee, and all participants provide written informed consent prior to enrollment.

This trial is expected to provide evidence on the effectiveness of structured telenursing interventions in oncology, supporting the integration of remote nursing care models into routine clinical practice. If effective, this approach may contribute to improving patient safety, enhancing treatment adherence, reducing healthcare utilization, and optimizing overall outcomes in patients receiving CDK inhibitor therapy.

03

Conditions studied

  • Breast Cancer
  • Drug-Related Side Effects and Adverse Reactions
  • Chemotherapy Toxicity
  • Treatment Adherence
  • Treatment-Related Toxicity

Keywords

  • Breast Cancer
  • Telenursing
  • Telemedicine
  • Cyclin-Dependent Kinase Inhibitors
  • CDK4/6 Inhibitors
  • Treatment Toxicity
  • Adverse Events
  • Supportive Care
  • Treatment Adherence
  • Oncology Nursing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged ≥18 years
  • confirmed breast cancer
  • Ongoing treatment with CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib)
  • Ability to understand and provide
  • Access to a telephone or digital communication device for telenursing follow-up

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with the study procedures
  • Cognitive impairment or psychiatric conditions interfering with participation
  • Participation in another interventional clinical trial that may affect study outcomes
  • Severe comorbidities limiting or follow-up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Active comparator
    Standard Care

    Participants receive routine clinical and nursing management according to standard local practice during treatment with CDK inhibitors.

    Other: Standard Nursing Care

  • Experimental
    Telenursing Intervention

    Participants receive routine care plus a structured telenursing follow-up program with scheduled remote nursing contacts during treatment with CDK inhibitors.

    Behavioral: Structured Telenursing Follow-up

Interventions

  • BehavioralStructured Telenursing Follow-up

    A structured telenursing follow-up program consisting of scheduled telephone or video consultations conducted by trained oncology nurses during treatment with CDK inhibitors. The intervention includes systematic symptom assessment, patient education, adherence support, and early identification and management of treatment-related adverse events.

  • OtherStandard Nursing Care

    Routine clinical and nursing care provided according to standard local practice, including scheduled outpatient visits and patient-initiated contacts as needed.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events assessed by CTCAE (v5.0)

    Incidence of treatment-related adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, during CDK 4/6 inhibitor therapy.

    Time frame: From treatment initiation up to 6 months

Secondary outcomes

  1. Severity of adverse events assessed by CTCAE (v5.0)

    Incidence of treatment-related adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events will be classified by grade (1-5), with higher grades indicating increased severity.

    Time frame: Up to 6 months

  2. Treatment adherence assessed by dose intensity and treatment interruptions

    Treatment adherence evaluated as relative dose intensity (RDI), expressed as the percentage of the prescribed dose actually received (0-100%), with higher values indicating better adherence.

    Time frame: Up to 6 months

  3. Rate of unplanned hospital visits related to treatment toxicity

    Number of unplanned emergency department visits or hospital admissions related to treatment-related adverse events during the study period.

    Time frame: Up to 6 months

  4. Quality of life assessed by EORTC QLQ-C30 questionnaire

    Patient-reported quality of life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scores range from 0 to 100; higher scores indicate better functioning for functional scales and worse symptom burden for symptom scales.

    Time frame: Baseline to 6 months

  5. Time to detection of adverse events (patient-reported vs clinically identified)

    Time interval between patient-reported onset of symptoms and clinical identification of treatment-related adverse events, measured in days.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Cardinal Massaia Hospital - S.C. Oncology, Azienda Sanitaria Locale AT (ASL AT)
    Asti, ASTI 14100, Italy
    Recruiting
    • MANUELA CANICATTI', RN, MSc, PhD(c) · Contactmcanicatti@asl.at.it · +39 03297278131
    • MANUELA CANICATTi', RN, MSc, PhD(c) · Principal investigator
08

References and documents

Publications

  • Yahyaei A, Madani T, Vesali S, Mashayekhi M. Intrauterine infusion of autologous platelet rich plasma can be an efficient treatment for patients with unexplained recurrent implantation failure. Sci Rep. 2024 Oct 29;14(1):26009. doi: 10.1038/s41598-024-77578-1. PubMed 39472511 ↗
  • Hsieh CY, Lin CC, Huang YW, Chen JH, Tsou YA, Chang LC, Fan CC, Lin CY, Chang WC. Macrophage secretory IL-1beta promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling. JCI Insight. 2022 Dec 8;7(23):e157285. doi: 10.1172/jci.insight.157285. PubMed 36264639 ↗
  • Robinson NB, Gaudino M. Commentary: Acute type A dissection and sex: A matter of biology or of imperfect adjustment? J Thorac Cardiovasc Surg. 2023 Mar;165(3):982-983. doi: 10.1016/j.jtcvs.2021.04.005. Epub 2021 Apr 12. No abstract available. PubMed 33958197 ↗
  • Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Harnoy Y, Boudjema K, Meunier B, Sulpice L. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016 Apr;113(5):575-80. doi: 10.1002/jso.24165. Epub 2016 Jan 18. PubMed 26776934 ↗
  • Sood A, Midha V, Goyal O, Goyal P, Sood P, Sharma SK, Sood N. Skin and soft tissue infections in cirrhotics: a prospective analysis of clinical presentation and factors affecting outcome. Indian J Gastroenterol. 2014 May;33(3):281-4. doi: 10.1007/s12664-014-0454-2. Epub 2014 Apr 5. PubMed 24706053 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to privacy and confidentiality restrictions. The dataset contains sensitive clinical information, and data sharing is not planned within the scope of this study. Aggregated results will be disseminated through scientific publications and presentations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2028, 48 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 48 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 13, 2026
StartActual
Apr 9, 2024
Primary completionEst.
Apr 2028
CompletionEst.
Sep 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07524829
Lead sponsor
Azienda Sanitaria Locale di Asti
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 9, 2024
Primary completion
Apr 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

MANUELA CANICATTI', RN, MSc, PhD(c)
Contact
mcanicatti@asl.at.it
+39 3297278131 ext. +39 0141486557
MANUELA CANICATTI', RN, MSc, PhD(c)
principal investigator · ASL AT
Michela PIREDDA, RN, MSc, PhD
study director · University of Rome Tor Vergata, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion